MANNKIND CORP 8-K

What Happened
MannKind Corporation (MNKD) announced in an 8-K filed May 28, 2026 that the U.S. Food and Drug Administration (FDA) has released the company from a five‑year, randomized, controlled postmarketing requirement (PMR) that had called for 8,000–10,000 patients to assess pulmonary malignancy risk with Afrezza. The company said the only remaining PMR for Afrezza is an assessment of efficacy and safety in pediatric patients. MannKind also noted the FDA accepted a supplemental BLA for Afrezza in children and adolescents (ages 4–17) in October 2025, with a PDUFA target action date of May 29, 2026. Separately, MannKind reported clinical progress on INHALE‑1st, a study of Afrezza plus basal insulin in youth aged 10–17, with eight additional sites activated and up to 100 participants expected.

Key Details

• FDA released MannKind from the five‑year randomized PMR (originally planned for 8,000–10,000 patients) related to pulmonary malignancy concerns.
• Remaining postmarketing requirement: pediatric efficacy and safety assessment.
• Supplemental BLA for ages 4–17 was accepted for review in Oct 2025; PDUFA target date: May 29, 2026.
• INHALE‑1st: 8 additional sites activated (10 total); up to 100 participants; main phase 13 weeks, optional extension to 26 weeks; primary endpoint = % of participants with time in range (70–180 mg/dL) ≥70% during the 14 days before the 13‑week visit; data expected late 2027.
• Report signed May 28, 2026 by David Thomson, EVP, General Counsel and Secretary.

Why It Matters
Being released from the very large pulmonary‑malignancy PMR removes a significant long‑term regulatory burden and uncertainty tied to Afrezza, which could reduce potential future costs and operational constraints for MannKind. The pending pediatric sBLA decision (PDUFA May 29, 2026) is a near‑term regulatory milestone that could expand Afrezza’s label to children and adolescents if approved. Continued enrollment and site activation in INHALE‑1st provide a path to clinical data in youth with type 1 diabetes (readout expected late 2027). Investors should note these are regulatory and clinical updates rather than financial results; the filing reiterates standard forward‑looking statement cautions.